OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Response to media comment
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment on the AbC-19 Rapid Test and rejects the conclusions drawn on the performance of the test.
The fact remains that the Department of Health and Social Care (DHSC) is satisfied with the performance of the test, as is the UK-RTC. Public Health England conducted its own evaluation at the DHSC's request, and the DHSC will continue to deploy the test for use in surveillance studies . Accordingly, Omega does not believe the antibody testing opportunity through the UK-RTC has diminished.
Omega also welcomes the positive news on the progress of a viable vaccine and believes the need for COVID-19 antibody testing generally has not gone away and will continue for some considerable time.
Contacts:
|
Omega Diagnostics Group PLC |
Tel: 01259 763 030 |
|
Bill Rhodes, Interim Non-Executive Chairman Colin King, Chief Executive |
|
|
Kieron Harbinson, Group Finance Director |
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
|
Geoff Nash/Edward Whiley (Corporate Finance) |
|
|
Alice Lane (ECM) |
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
|
Paul McManus |
Mob: 07980 541 893 |
|
Lianne Cawthorne |
Mob: 07584 391 303 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.